Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Indaptus Therapeutics Inc

Healthcare US INDP

3.41USD
0.15(4.60%)

Last update at 2026-06-26T20:00:00Z

Day Range

3.263.82
LowHigh

52 Week Range

1.564.08
LowHigh

Fundamentals

  • Previous Close 3.26
  • Market Cap20.24M
  • Volume134706
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-16.37719M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.77

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -14.32280M -7.71139M -3.58415M -
Minority interest - - - -
Net income -13.73469M -7.69366M -3.56904M -
Selling general administrative 8.59M 5.21M 0.94M -
Selling and marketing expenses - - - -
Gross profit - - - -
Reconciled depreciation 0.00178M 0.00140M 0.00085M -
Ebit -14.91091M -7.72911M -3.59926M -2.63171M
Ebitda -14.90912M -7.72771M -3.59841M -
Depreciation and amortization 0.00178M 0.00140M 0.00085M -
Non operating income net other - - - -
Operating income -14.91091M -7.72911M -3.59926M -
Other operating expenses 14.91M 7.73M 3.60M -
Interest expense 0.59M 0.02M 0.02M 0.00000M
Tax provision - - - -
Interest income 0.59M 0.02M 0.02M -
Net interest income 0.59M 0.02M 0.02M -
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense -0.58811M -0.01772M -0.01511M -
Total revenue 0.00000M 0.00000M 0.00000M -
Total operating expenses 14.91M 7.73M 3.60M -
Cost of revenue - - - -
Total other income expense net 0.59M 0.02M 0.02M -
Discontinued operations - - - -
Net income from continuing ops -14.32280M -7.71139M -3.58415M -
Net income applicable to common shares -14.32280M -7.71139M -3.58415M -2.56521M
Preferred stock and other adjustments - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 14.92M 28.06M 40.58M 1.78M -
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.63M 0.81M 1.23M 0.09M 0.04M
Total liab 2.85M 3.43M 4.68M 2.02M -
Total stockholder equity 12.08M 24.63M 35.90M -0.23770M -
Deferred long term liab - - - - -
Other current liab 1.87M 1.97M 1.87M 1.86M 0.25M
Common stock 0.08M 0.08M 0.08M 0.02M 0.00073M
Capital stock 0.08M 0.08M 0.08M 0.03M -
Retained earnings -45.41716M -29.99368M -15.67089M -7.95950M -4.37535M
Other liab - - - - -
Good will - - - - -
Other assets - 0.74M 0.02M 0.04M 0.05M
Cash 13.36M 9.63M 39.13M 1.64M -
Cash and equivalents - - - - -
Total current liabilities 2.77M 3.43M 4.60M 2.02M 0.73M
Current deferred revenue - - - - -
Net debt -13.18700M -9.54631M -38.96284M -1.63750M -
Short term debt 0.10M 0.08M 0.10M 0.10M -
Short long term debt - - - - -
Short long term debt total 0.18M 0.08M 0.17M 0.17M -
Other stockholder equity 57.41M 54.44M 51.49M 7.69M -
Property plant equipment - 0.08M 0.17M 0.00135M 0.00220M
Total current assets 14.00M 27.24M 40.39M 1.73M 3.90M
Long term investments - - - - -
Net tangible assets - 24.63M 35.90M -0.23802M 3.21M
Short term investments 0.00000M 16.81M - - -
Net receivables - - 0.02M - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 0.81M 1.38M 2.64M 0.16M 0.03M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00000M 0.10M - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.75M 0.74M 0.02M 0.04M -
Deferred long term asset charges - - - - -
Non current assets total 0.93M 0.82M 0.19M 0.05M -
Capital lease obligations 0.18M 0.08M 0.17M 0.00000M -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -16.42702M 0.45M -16.59957M -16.59957M
Change to liabilities -1.15483M -4.23666M 0.11M 0.38M
Total cashflows from investing activities -16.42702M 0.45M 0.45M -0.00255M
Net borrowings - - 1.16M 0.25M
Total cash from financing activities 0.00000M 48.34M 1.16M 0.25M
Change to operating activities -0.42559M -0.85415M 0.00481M -0.06817M
Net income -14.32280M -7.71139M -3.58415M -2.56521M
Change in cash -29.50537M 37.49M -2.16146M -1.88449M
Begin period cash flow 39.13M 1.64M 3.80M -
End period cash flow 9.63M 39.13M 1.64M 3.80M
Total cash from operating activities -13.07835M -11.29054M -3.32463M -2.13193M
Issuance of capital stock 0.00000M 5.00M 1.16M -
Depreciation 0.00178M 0.00140M 0.00085M 0.00036M
Other cashflows from investing activities 0.17M 0.45M 0.45M 0.45M
Dividends paid - - - -
Change to inventory - - - -
Change to account receivables - - - -
Sale purchase of stock - - - -
Other cashflows from financing activities -16.42702M 43.34M 48.34M 0.25M
Change to netincome 2.82M 1.51M 0.14M 0.12M
Capital expenditures 0.00000M 0.00385M 0.00385M 0.00255M
Change receivables - - - -
Cash flows other operating - - - -
Exchange rate changes - - - -
Cash and cash equivalents changes - - - -
Change in working capital -1.58042M -5.09081M 0.12M -
Stock based compensation 2.96M 1.51M 0.14M -
Other non cash items -0.13416M - -5.09081M -
Free cash flow -13.07835M -11.29439M -3.32463M -

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
INDP
Indaptus Therapeutics Inc		 0.15 4.60% 3.41 - - - 2.15 1.03
NVO
Novo Nordisk A/S		 0.43 0.90% 48.07 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 47.84 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 11.16 2.32% 491.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 12.76 2.06% 632.90 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Indaptus Therapeutics Inc

Three Columbus Circle, New York, NY, United States, 10019

Key Executives

Name Title Year Born
Mr. Jeffrey A. Meckler CEO & Director 1967
Dr. Michael J. Newman Ph.D. Founder, Chief Scientific Officer & Director 1956
Mr. Walt Addison Linscott Esq. Chief Bus. Officer 1961
Mr. Nir Sassi CFO, Sec. & Treasurer 1976
Dr. Boyan Vesselinov Litchev M.D. Chief Medical Officer 1967
Mr. Walt Addison Linscott Esq. Chief Operating Officer 1961
Dr. Michael J. Newman Ph.D. Founder, Chief Scientific Officer & Director 1957
Mr. Nir Sassi CFO, Secretary & Treasurer 1976
Dr. Roger J. Waltzman M.B.A., M.D. Chief Medical Officer 1969

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions